Merck oncology revenue growth and drug approvals
Statements (26)
- Bullish
Merck and BioNTech stock prices increased due to higher market attention from the oncology congress.
- Bullish
Merck & Co. may see increased demand for its cancer treatment products following the vaccine breakthrough in the trial.
- Bullish
Merck stock surges on mRNA cancer vaccine results
- Bullish
Merck shares surged following the same personalized mRNA cancer therapy Phase 3 win in melanoma.
- Bullish
Merck & Co. shares rose 10% on Wednesday following disclosure of melanoma treatment trial results
- Bullish
Merck stock jumped 7% following positive trial results
- Bullish
Merck stock jumped on late-stage cancer vaccine trial win
- Bullish
Merck stock surged 8.01% at $146 per share following melanoma vaccine news
- Bullish
Merck is likely to see further gains as its melanoma vaccine approval is expected to boost investor confidence.
- Bullish
Merck KGaA raised its 2026 outlook for organic sales
- Bullish
Merck KGaA reported strong Q2 growth with organic sales up 4.1% and EBITDA pre rising 9.3% organically to €1.6 billion
- Bullish
Merck KGaA raises its outlook on robust results due to stronger demand in life-science and electronics markets.
- Neutral
Merck raised its 2026 revenue guidance to $66.3 billion to $67.3 billion.
- Neutral
Merck & Co. reported Q2 revenue of $16.6 billion, a 5% increase year over year.
- Bullish
Merck MRK-N reported higher-than-expected second-quarter sales
- Bullish
Merck MRK-N is likely to see its stock price rise as it raises its full-year revenue forecast due to higher-than-expected second-quarter sales from Keytruda.
- Bullish
Merck reported quarterly revenue of $16.61 billion
- Bullish
Merck reported higher-than-expected second-quarter sales on Tuesday
- Bullish
Merck's quarterly revenue was up 5% from a year earlier
- Bullish
Merck is likely to see its stock price rise due to its reported higher-than-expected second-quarter sales and raised full-year revenue forecast driven by Keytruda strength.
- Bullish
Merck raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda
- Bullish
Merck hiked revenue outlook as new drug sales grew
- Bullish
Merck & Co. reported second-quarter sales of $16.6 billion, up 5% from the same period last year
- Bullish
Merck raises 2026 sales forecast due to strength of newer drugs
- Bullish
Merck delivers a clean earnings beat on oncology strength
- Bullish
Merck & Co. (MRK) is likely to see positive market reaction due to its announcement of a $5B growth opportunity in HIV treatment and prevention, which could boost investor confidence in the company's pipeline and future revenue potential.